Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-04-13 23:00 |
Biophytis découvre un rapport erroné concernant l‘étude COVA
|
French | 112.0 KB | ||
| 2021-03-22 08:00 |
Biophytis gives updates on its Phase 2-3 COVA study on COVID-19
|
English | 550.0 KB | ||
| 2021-03-22 08:00 |
Biophytis fait le point sur son étude de Phase 2-3 COVA sur la COVID-19
|
French | 554.7 KB | ||
| 2021-03-19 20:00 |
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophyt…
|
English | 134.6 KB | ||
| 2021-03-12 21:15 |
RAPPORT FINANCIER ANNUEL2020
|
French | 3.7 MB | ||
| 2021-03-10 20:00 |
Biophytis’ Combined Annual General Meeting Will Take Place on April 26, 2021 be…
|
English | 183.3 KB | ||
| 2021-03-10 20:00 |
L’Assemblée Générale Mixte de Biophytis aura lieu le 26 avril 2021 à huis-clos
|
French | 255.9 KB | ||
| 2021-02-26 08:00 |
Biophytis annonce ses résultats annuels 2020
|
French | 407.5 KB | ||
| 2021-02-26 08:00 |
Biophytis Reports 2020 Full Year Results
|
English | 354.9 KB | ||
| 2021-02-17 08:00 |
Biophytis annonce l’extension du recrutement des patients pour la Partie 2 de l…
|
French | 227.3 KB | ||
| 2021-02-17 08:00 |
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-…
|
English | 227.4 KB | ||
| 2021-02-15 08:00 |
Biophytis annonce le Règlement-Livraison de son Offre ADS
|
French | 244.9 KB | ||
| 2021-02-10 15:16 |
Biophytis annonce la reprise des négociations de ses actions ordinaires et de s…
|
French | 217.2 KB | ||
| 2021-02-10 08:00 |
Biophytis annonce la Fixation du Prix de son Offre ADS et l’Approbation de l’Ad…
|
French | 320.4 KB | ||
| 2021-02-03 08:00 |
Biophytis annonce le démarrage du recrutement des patients au Brésil et aux Éta…
|
French | 240.1 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
